Latest news with #MRNA
Yahoo
4 days ago
- Business
- Yahoo
3 of Wall Street's Favorite Stocks That Fall Short
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it's worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover. Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals. Jamf (JAMF) Consensus Price Target: $17.45 (112% implied return) Founded in 2002 by Zach Halmstad and Chip Pearson, right around the time when Apple began to dominate the personal computing market, Jamf (NASDAQ:JAMF) provides software for companies to manage Apple devices such as Macs, iPads, and iPhones. Why Do We Think Twice About JAMF? Revenue increased by 17.7% annually over the last three years, acceptable on an absolute basis but tepid for a software company enjoying secular tailwinds Average billings growth of 8.9% over the last year was subpar, suggesting it struggled to push its software and might have to lower prices to stimulate demand Suboptimal cost structure is highlighted by its history of operating margin losses Jamf is trading at $8.22 per share, or 1.6x forward price-to-sales. Read our free research report to see why you should think twice about including JAMF in your portfolio, it's free. Moderna (MRNA) Consensus Price Target: $47.59 (47.1% implied return) Rising to global prominence during the COVID-19 pandemic with one of the first effective vaccines, Moderna (NASDAQ:MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases. Why Do We Steer Clear of MRNA? Historically negative EPS is a worrisome sign for conservative investors and obscures its long-term earnings potential Capital intensity has ramped up over the last five years as its free cash flow margin decreased by 309.9 percentage points Limited cash reserves may force the company to seek unfavorable financing terms that could dilute shareholders Moderna's stock price of $32.36 implies a valuation ratio of 6x forward price-to-sales. Check out our free in-depth research report to learn more about why MRNA doesn't pass our bar. Kemper (KMPR) Consensus Price Target: $82.20 (37% implied return) Originally known as Unitrin until rebranding in 2011, Kemper (NYSE:KMPR) is an insurance holding company that provides automobile, homeowners, life, and other insurance products to individuals and businesses across the United States. Why Do We Pass on KMPR? Net premiums earned tumbled by 2.4% annually over the last four years, showing market trends are working against its favor during this cycle Performance over the past five years shows each sale was less profitable as its earnings per share dropped by 2.8% annually, worse than its revenue Policy losses and capital returns have eroded its book value per share this cycle as its book value per share declined by 4.5% annually over the last five years At $60 per share, Kemper trades at 1.3x forward P/B. If you're considering KMPR for your portfolio, see our FREE research report to learn more. High-Quality Stocks for All Market Conditions When Trump unveiled his aggressive tariff plan in April 2024, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that's already erased most losses. Don't let fear keep you from great opportunities and take a look at Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Reuters
4 days ago
- Business
- Reuters
Moderna cancels plans to build Japan plant on poor business environment
July 18 (Reuters) - Moderna (MRNA.O), opens new tab said on Friday it is cancelling plans to build a messenger RNA manufacturing plant in Japan due to "changes in the business environment" around the world and in Japan.
Yahoo
08-07-2025
- Business
- Yahoo
The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.
Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when its mRNA-based COVID-19 vaccine was one of the first to be granted emergency-use authorization and distributed globally. This opportunity also validated Moderna's mRNA platform's effectiveness and scalability, boosting the company's stock price by more than 1,200% between 2020 and 2022. Another such clinical-stage contender generating growing excitement is Intellia Therapeutics (NTLA), a CRISPR/Cas9-based gene-editing company. Intellia aims to provide one-time, curative treatments for serious genetic diseases. Intellia's stock has fallen 1.9% year-to-date, while the broader market, as tracked by the S&P 500 Index ($SPX), has risen 6%. This Analyst Just Raised His Broadcom Stock Price Target by 70%. Should You Buy AVGO Now? Why Alibaba Stock Looks Like a Screaming Buy After Falling 27% From Its 2025 Highs 2 ETFs Offering Juicy Dividend Yields of 20% or Higher Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. Let's dig deeper to see if this could be the next transformative biotech story that reshapes medicine — and markets — in the same way Moderna did. Intellia employs a dual-platform strategy, focusing on both in vivo (inside the patient's body) and ex vivo (outside the patient's body) approaches to treating conditions such as transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE). Intellia's lead in vivo therapies include NTLA-2001 (Nexiguran ziclumeran or nex-z), a treatment for ATTR amyloidosis that is in the Phase 3 MAGNITUDE trial. Nex Z was also granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the U.S. Food and Drug Administration (FDA), indicating its potential for accelerated development. NTLA-2002, a treatment for hereditary angioedema (HAE), is now in late-stage clinical trials. In the first quarter of 2025, Intellia administered the first dose in the HAELO trial. This event marks a critical inflection point, bringing Intellia closer to regulatory filings and possible approval. However, the company recently halted its NTLA-3001 lung disease candidate, as well as several other research programs. It also reduced its workforce by about 27%, causing a short-term disruption. The goal of this strategic reorganization is to increase focus on late-stage assets while conserving capital. While Intellia does not yet generate product revenue, it did generate $16.6 million in collaboration revenue during the first quarter. As of Q1 end, the company held $707.1 million in cash and executed a 27% workforce reduction, ensuring a runway until the first half of 2027. Intellia's first-mover advantage in in vivo gene editing could propel it to great success if its candidates are approved. The company has also collaborated with heavyweights like Regeneron (REGN), gaining expertise, resources, and a broader clinical reach. However, as a clinical-stage biotech company, the company faces the risk of clinical trials failing or delays in regulatory approvals because gene editing is a high-stakes game. Furthermore, increased cash burn may necessitate dilution. Long-term growth investors who believe in CRISPR's transformative potential may view NTLA stock as an enticing but high-risk investment opportunity. Overall, Wall Street has assigned Intellia stock a 'Moderate Buy' rating. Of the 27 analysts covering NTLA stock, 19 have a 'Strong Buy' recommendation, one suggests a 'Moderate Buy,' six say it is a 'Hold,' and one suggests a 'Strong Sell.' The average price target of $38.04 implies the stock has upside potential of 245% over current levels. Plus, the Street-high price estimate of $106 suggests the stock can rally over 860% over the next 12 months. While the upside appears out of reach, Moderna stock is a prime example of how a single successful product can propel a biotech stock toward the skies. Intellia, like Moderna, focuses on diseases with high clinical need and, if successful, has the potential to transform medicine. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
NDTV
07-07-2025
- Health
- NDTV
Karnataka To Treat Sudden Deaths As "Notifiable Disease", Says Health Minister
Bengaluru: The Karnataka government on Monday decided to treat sudden deaths as "notifiable disease" and conduct postmortem in such cases. State Health Minister Dinesh Gundu Rao said there will be more screening of people above the age of 15 years in the state. The minister's remarks came in the wake of a spate of heart attacks in the state, especially in Hassan district. He also sought to clarify that Chief Minister Siddaramaiah's statement linking Covid vaccine with the spate of heart attacks was not with any malafide intention. "We have decided to announce sudden deaths as a notifiable disease. The government should be notified if sudden deaths happen outside hospitals," Mr Rao said in a press conference. He said autopsy will be made compulsory in cases of sudden deaths. The minister underlined the need for screening more people, including children about 15 years of age at least once a year "because there are people who have diseases since birth". Mr Rao also announced incorporating a subject on heart attacks and diseases causing sudden deaths in the textbooks. "We have sent a format to the education department to include a chapter on sudden deaths in their curriculum. This will be included in next academic year," Mr Rao said. It has also been decided to impart training to people on cardiopulmonary Resuscitation (CPR). Further, the Puneeth Rajkumar Hrudaya Jyoti scheme, which is going on in 86 hospitals in the state, will be extended to Taluk level hospitals this year, the minister said. The scheme is aimed at providing treatment to people suffering sudden heart attacks. Citing a report by an expert committee set up by the Karnataka government to an investigation into sudden cardiovascular deaths and their possible association with Covid-19 infection and vaccination, Rao said Covid and not its vaccine be the reason behind heart attacks and sudden deaths. "After Covid there is also spurt in diabetes. Those who died of heart attacks had the risk factors of diabetes, blood pressure and obesity. Covid's effect is quite evident on people because the patients had taken various medicines during that time and there was lack of physical activities," he explained. "Covid vaccine was not directly responsible for the cardiac arrests. There were several researches at the national level. The vaccines have benefited people, especially the one we took in India," Mr Rao said. The minister, however, pointed out that there is some doubt about MRNA vaccines, which were not administered in India. "It has been slightly found that the MRNA vaccine has caused myocarditis (inflammation of heart muscles)," Mr Rao said. On Siddaramaiah's statement linking Covid vaccine with the spate of heart attacks, the minister explained, "the CM's intention was good but some people mistook it. He wanted to know about the side effects of Covid and its vaccine." Siddaramaiah came in for sharp criticism for attributing Covid vaccines for a series of heart attacks in the state. "It cannot be denied that the hasty approval and distribution of the Covid vaccine to the public could also be a reason for these deaths, as several studies worldwide have recently indicated that COVID vaccines could be a cause for the increasing number of heart attacks. Before BJP criticize us on this matter, they should ask their conscience," the CM had said in a post on 'X'.
Yahoo
06-07-2025
- Business
- Yahoo
Where Will Moderna Be in 10 Years?
After soaring in early pandemic days, Moderna has fallen into the doldrums. An explosive phase of growth may be ahead thanks to several potential product launches. 10 stocks we like better than Moderna › A lot can happen in 10 years, and that's good news for a struggling stock like Moderna (NASDAQ: MRNA). Once a stock market star generating billions of dollars in coronavirus vaccine revenue, Moderna in more recent times has faced declining demand for that product and therefore declining sales and stock performance. In fact, the shares have lost more than 90% since their peak back in 2021. But before you give up on this biotech player, it's important to look at the reason behind today's troubles and consider the company's long-term potential. After all, you could pick up one share of Moderna for less than $30, making it easy to add a few to your portfolio. Where will Moderna be in 10 years? Let's find out. Let's first take a step back and catch up on the Moderna story so far. This biotech surged to center stage in early pandemic days as it brought its coronavirus vaccine to market and generated annual product revenue of as much as $18.4 billion at its highest. This also resulted in billions of dollars in profit for Moderna. But as the pandemic evolved into its later stages, demand for vaccines waned, and that resulted in significant declines in sales for the company. Initially the coronavirus vaccine was Moderna's only product, but the company then won approval for a respiratory syncytial virus (RSV) vaccine last year. Unfortunately for Moderna, that vaccine's sales disappointed in its early days on the market. As a response to all of this, Moderna has launched a major cost realignment plan and is making progress on that. In the recent quarter, the biotech said it would reduce GAAP operating costs by as much as $1.7 billion by 2027. Meanwhile, the company also is making research and development a priority, and here, the excellent news is Moderna has a full late-stage pipeline. In fact, Moderna aims to launch as many as 10 new products within the next three years, though those launches are not guaranteed. Now, let's look at the point I made above about the reason behind the company's poor performance in recent times. This is primarily due to the decline in coronavirus revenue and the fact that Moderna hasn't yet launched another big growth product. It's important to keep in mind that the coronavirus vaccine reached such huge sales figures because it addressed a pandemic situation. It's to be expected that sales declined as the crisis waned. And investors shouldn't focus on that when looking at Moderna today or considering the company's future prospects. As for new product launches, the development of candidates and the regulatory process take time; regulators acted quickly to approve vaccines during the pandemic but that was an exceptional situation. Potential products outside of pandemic situations require years of development and often many months for regulatory consideration. So, it isn't surprising that Moderna hasn't yet launched a great number of additional products. With all of this in mind, let's look ahead to a decade from now. Where will Moderna be? Moderna expects many new products to launch in just a few years, so it's possible that in 10 years, Moderna could have about 10 products on the market. These may include several cancer vaccines, as right now candidates for melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma all are involved in late-stage trials. Moderna also may have launched its cytomegalovirus (CMV) vaccine, and many respiratory virus vaccines such as a combined coronavirus/flu shot. Of course, there's the possibility of candidate failure even in late-stage trials, but Moderna so far has delivered a strong success rate. Its probability of success in phase 3 trials is 83% -- that's compared to the industry average of 69%. Moderna also has predicted that by 2028, it will break even on an operating cash cost basis and generate $6 billion in revenue. In fact, new product launches from 2026 through 2028 should result in a compounded annual growth rate of 25% or more, the company says. All of this suggests that, a decade from now, even if Moderna only partially meets its product launch goals, the company could have a significant number of products on the market, and might deliver double-digit revenue growth. Moderna stock is indeed in the doldrums today, but this offers the opportunity to buy at a reasonable price, and, 10 years down the road, potentially benefit from a huge biotech growth story. Before you buy stock in Moderna, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Moderna wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $699,558!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $976,677!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool recommends Moderna. The Motley Fool has a disclosure policy. Where Will Moderna Be in 10 Years? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
